# A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors

> **NCT01954043** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 23 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Dabrafenib 150 mg twice a day (BID)
- **DRUG:** Rabeprazole 40 mg once daily (OD)
- **DRUG:** Rifampin 600 mg OD

## Key facts

- **NCT ID:** NCT01954043
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-20
- **Primary completion:** 2016-02-29
- **Final completion:** 2016-02-29
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2017-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01954043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01954043, "A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01954043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*